News Breaks |
|
|
| September 6, 2012 |
| 08:04 EDT |  | NDZ | Nordion provides update on Phase III TheraSphere trial
Nordion provided an update on its YES-P clinical trial for TheraSphere®, the company’s Yttrium-90 glass microsphere liver cancer treatment, by naming the principal investigators and contract research organization for the study. The YES-P trial is targeting enrollment of 350 patients at approximately 24 sites in Europe, with additional sites to be identified globally. The study will follow a randomized two-armed design – in one arm, patients will undergo Y-90 radioembolization treatment with TheraSphere®, while patients in the other arm will receive sorafenib, the standard of care for advanced unresectable HCC. |
|
|
News For NDZ From The Last 14 Days Check below for free stories on NDZ the last two weeks. |
|
|
| May 24, 2013 |
| 09:37 EDT |  | NDZ | Nordion downgraded to Reduce from Hold at TD Securities
 Subscribe for More Information |
|
| May 23, 2013 |
| 15:01 EDT |  | NDZ | Nordion upgraded to Buy from Neutral at Sidoti
Subscribe for More Information |
|
| 05:33 EDT | | NDZ | Nordion divests Targeted Therapies business to BTG for $200M
Nordion announced that it has entered into an agreement to divest its Targeted Therapies business to BTG plc, an international specialist healthcare company based in London, United Kingdom, for a cash purchase price of $200M. Net of cash taxes and transaction costs, Nordion expects to realize approximately $185M on closing. The transaction is anticipated to be completed by the end of June. |
|
| May 16, 2013 |
| 07:28 EDT |  | NDZ | I/O Central to host a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 16:37 EDT | | NDZ | Nordion signs contract manufacturing agreement with Navidea
Subscribe for More Information |
|
| May 14, 2013 |
| 10:01 EDT |  | NDZ | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 09:15 EDT | | NDZ | Nordion initiated with a Neutral at Sidoti
Subscribe for More Information |
|
|
|
|
|
